Stock Financial Ratios, Dividends, Split History

TISI / Team, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price22.15
Volume227,300.00
Market Cap ($M)625.24
Enterprise Value ($M)1,013.94
Book Value ($M)449.94
Book Value / Share15.00
Price / Book1.44
NCAV ($M)-201.58
NCAV / Share-6.72
Price / NCAV-3.22
Share Statistics
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Outstanding 1,100,000
Weighted Average Number Of Shares Outstanding Basic 29,849,000
Weighted Average Number Of Diluted Shares Outstanding 29,849,000
Common Shares Outstanding 29,987,116
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.12
Return on Assets (ROA)-0.09
Return on Equity (ROE)-0.19
Balance Sheet (mrq) ($M)
Assets1,041.15
Liabilities591.22
Quick Ratio2.32
Current Ratio2.67
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue0.00
Sales Revenue Net1,200,211,000.00
Operating Income-115.11
Net Income-104.16
Earnings Per Share Basic-3.49
Earnings Per Share Diluted-3.49
Cash Flow Statement (mra) ($M)
Cash From Operations-13.73
Cash from Investing-34.00
Cash from Financing-34.00
Identifiers and Descriptors
CUSIP878155100
Central Index Key (CIK)318833
Related CUSIPS
878155900

Split History

Stock splits are used by Team, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Zeti: Malaysia will honour debt obligations

2018-05-14 thestar.com.my
KUALA LUMPUR: The Team of Eminent Persons has given an assurance that Malaysia will honour its debt obligations under the new government and highlighted that the current political changes in the country are happening at “a very positive time”. (5-0)

Team (TISI) Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the First Quarter 2018 Team, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. (5-0)

Askeladden Capital - Q1 2018 Letter: 'The Asterisks'

2018-04-02 seekingalpha
In my last letter, I noted that the early days of 2018 had been kind to our portfolio, more or less making up for a frustrating 2017 in which the market rallied without abandon, yet refused to recognize (or actively punished) good fundamentals at most of our portfolio companies. Here's how we're doing now. As always, please remember that we do not use leverage and typically maintain a double-digit cash balance. (195-1)

Team's (TISI) CEO Amerino Gatti on Q4 2017 Results - Earnings Call Transcript

2018-03-14 seekingalpha
Good day, ladies and gentlemen, and welcome to the Team, Inc. Fourth Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instruction] As a reminder, today’s conference is being recorded. (5-0)

CUSIP: 878155100